Microvessel area as a predictor of sorafenib response in metastatic renal cell carcinoma.

ABSTRACT:

Background

Sorafenib was the first Food and Drug Administration approved anti-angiogenic therapy for renal cell carcinoma (RCC). Currently, there are no validated predictive biomarkers for sorafenib. Our purpose was to determine if sorafenib target expression is predictive of sorafenib sensitivity.

Methods

We used an automated, quantitative immunofluorescence-based method to determine expression levels of sorafenib targets VEGF, VEGF-R1, VEGF-R2, VEGF-R3, c-RAF, B-RAF, c-Kit, and PDGFR-β in a cohort of 96 patients treated with sorafenib. To measure vasculature in the tumor samples, we measured microvessel area (MVA) by CD-34 staining.

Results

Of the markers studied, only high MVA was predictive of response (p = 0.005). High MVA was associated with smaller primary tumo

SUBMITTER: Aziz SA 

PROVIDER: S-EPMC3896780 | biostudies-literature | 2014 Jan

REPOSITORIES: biostudies-literature